Close Menu

NEW YORK (GenomeWeb) – DermTech announced today that its licensee, DermTech Canada, has received approval to market the company's pigmented lesions assay (PLA) and noninvasive biopsy kit for melanoma detection in Canada.

As part of the approval, DermTech will market and sell the PLA in Canada, while it will process samples at the company's central laboratory in La Jolla, California. The San Diego-based company said that coverage approvals are in process in Canada with an initial focus on British Columbia and Ontario.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.